Dr. Grüneberg Discusses Patent Eligibility at Lecture Series in Basel
On October 29, 2019, the Basel Intellectual Property Lecture (BIPL) series will be welcoming lecturer Dr. Kirsten Grüneberg, who will present on the Changing Landscape of Patent Eligibility in the U.S.
Subject matter eligibility has become a major topic in U.S. patent law in the past few years, with new developments from the Supreme Court in cases such as Alice v. CLS Bank, Mayo v. Prometheus, and AMP v. Myriad. While the U.S. Patent and Trademark Office has attempted to provide guidance for applicants in navigating the new territory in patent eligibility, the courts have cast significant doubt as to the efficacy of these guidelines in decisions such as Cleveland Clinic Foundation v. True Health Diagnostics. And as we have previously reported, the U.S. Congress has been exploring options for reform.
At the BIPL, Dr. Grüneberg will be characterizing the current and prospective landscape as to patent eligibility in the U.S., further offering practical advice for those seeking U.S. patent coverage in technical areas particularly affected by recent developments.
With support from Niizuma Wasner GmbH, F.Hoffmann-La Roche Ltd., the University of Basel, and the European Center of Pharmaceutical Medicine (EPCM), the BIPL provides a forum for discussions on intellectual property. Lecturers include legal professionals and researchers from across the globe. In presenting her upcoming lecture, Dr. Grüneberg joins a list of prestigious lecturers to appear at this lecture series. For further information, please contact firstname.lastname@example.org or BIPL@niizumawasner.com.
Launched in September 2017, Grüneberg and Myers PLLC is a 100 percent female- and minority-owned international patent firm. With a broad and sophisticated practice, the firm provides a full range of patent support services, including patent prosecution, counseling, post-grant representation, and M&A due diligence to meet the growing and diverse needs of U.S.-based, European, and Asian companies, entrepreneurs, and inventors.